Beam Therapeutics Inc. Increase (Decrease) in Contract with Customer, Liability
Beam Therapeutics Inc. (BEAM) reported Increase (Decrease) in Contract with Customer, Liability of -$6.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-04
- Beam Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$304.00K.
- Beam Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$6.36M.
- Beam Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$113.82M.
- Beam Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$5.66M.
- Beam Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was -$135.42M.
- Beam Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was -$36.52M.
- Beam Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was -$159.56M.
- Beam Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$35.92M, a 110.32% decline from fiscal 2021.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$304.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$6.66M 10-Q · filed 2026-08-04 | -$120.48M derived: sum of 3 quarters · filed 2026-08-04 | -$126.14M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$6.36M 10-Q · filed 2026-05-07 | -$120.17M derived: sum of 2 quarters · filed 2026-05-07 | -$125.84M derived: sum of 3 quarters · filed 2026-05-07 | -$134.30M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$113.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$119.48M derived: sum of 2 quarters · filed 2026-02-24 | -$127.95M derived: sum of 3 quarters · filed 2026-08-04 | -$135.42M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$5.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$14.13M derived: sum of 2 quarters · filed 2026-08-04 | -$21.60M 10-Q · filed 2025-11-04 | -$26.66M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$8.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$15.94M 10-Q · filed 2026-08-04 | -$21.00M derived: sum of 3 quarters · filed 2026-08-04 | -$34.27M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$7.47M 10-Q · filed 2026-05-07 | -$12.54M derived: sum of 2 quarters · filed 2026-05-07 | -$25.81M derived: sum of 3 quarters · filed 2026-05-07 | -$37.08M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$5.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$18.34M derived: sum of 2 quarters · filed 2026-02-24 | -$29.61M derived: sum of 3 quarters · filed 2026-02-24 | -$36.52M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$13.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$24.54M derived: sum of 2 quarters · filed 2025-11-04 | -$31.45M 10-Q · filed 2025-11-04 | -$130.99M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$11.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$18.18M 10-Q · filed 2025-08-05 | -$117.72M derived: sum of 3 quarters · filed 2026-02-24 | -$134.92M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$6.91M 10-Q · filed 2025-05-06 | -$106.45M derived: sum of 2 quarters · filed 2026-02-24 | -$123.64M derived: sum of 3 quarters · filed 2026-02-24 | -$142.76M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$99.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$116.73M derived: sum of 2 quarters · filed 2026-02-24 | -$135.85M derived: sum of 3 quarters · filed 2026-02-24 | -$159.56M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$17.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$36.31M derived: sum of 2 quarters · filed 2024-11-05 | -$60.02M 10-Q · filed 2024-11-05 | -$80.05M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$19.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$42.82M 10-Q · filed 2024-08-06 | -$62.86M derived: sum of 3 quarters · filed 2025-02-25 | -$78.66M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$23.71M 10-Q · filed 2024-05-07 | -$43.74M derived: sum of 2 quarters · filed 2025-02-25 | -$59.54M derived: sum of 3 quarters · filed 2025-02-25 | -$51.20M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$20.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$35.84M derived: sum of 2 quarters · filed 2025-02-25 | -$27.49M derived: sum of 3 quarters · filed 2025-02-25 | -$35.92M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$15.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$7.45M derived: sum of 2 quarters · filed 2023-11-08 | -$15.88M 10-Q · filed 2023-11-08 | $283.05M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $8.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$84.00K 10-Q · filed 2023-08-08 | $298.85M derived: sum of 3 quarters · filed 2024-02-27 | $298.08M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$8.43M 10-Q · filed 2023-05-10 | $290.50M derived: sum of 2 quarters · filed 2024-02-27 | $289.74M derived: sum of 3 quarters · filed 2024-02-27 | $339.73M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $298.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $298.17M derived: sum of 2 quarters · filed 2024-02-27 | $348.16M derived: sum of 3 quarters · filed 2024-02-27 | $348.16M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$764.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $49.23M derived: sum of 2 quarters · filed 2022-11-07 | $49.22M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $49.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $49.99M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | -$6.00K 10-Q · filed 2022-05-09 | |||
| 2020-06-30 | -$12.00K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |